As people living with IgA nephropathy (IgAN), we welcome the opportunity to share our perspective on the KDOQI US Commentary on the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV) in this issue of AJKD,1 and to include several quotes throughout from the first 2 authors of this piece.